Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for cancer, with a pipeline of differentiated small molecule hematology and oncology drug candiates. Currently Curis has two drugs candidates in development; CA-4948 an oraly available small molecule inhibitor of IRAK4 kinase in non-Hodgkin's lymphoma and leukemia (AML/MDS), and CI-8993 a clinical-stage human IgG1 kappa monoclonal antibody designed to antagonize the VISTA signaling pathway in advance solid tumors.